Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

OBJECTIVE: We undertook this phase III study to evaluate baricitinib, an orally administered JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis (RA) who had received no or minimal conventional synthetic d...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Arthritis Rheumatol
Autores principales: Fleischmann, Roy, Schiff, Michael, van der Heijde, Désirée, Ramos‐Remus, Cesar, Spindler, Alberto, Stanislav, Marina, Zerbini, Cristiano A. F., Gurbuz, Sirel, Dickson, Christina, de Bono, Stephanie, Schlichting, Douglas, Beattie, Scott, Kuo, Wen‐Ling, Rooney, Terence, Macias, William, Takeuchi, Tsutomu
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5347954/
https://ncbi.nlm.nih.gov/pubmed/27723271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39953
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares